Solid Biosciences (SLDB) said it will provide a corporate update at the J.P. Morgan Healthcare Conference later Wednesday outlining its expanded clinical-stage pipeline and 2025 objectives.

Among the highlights from the presentation include its SGT-003 for Duchenne muscular dystrophy and SGT-212 for Friedreich's ataxia, Solid said. It said SGT-003 continued to be well tolerated in the first four patients dosed in an ongoing trial.

The company said it has resources to fund its key strategic priorities into 2026.